
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Catch up with the latest developments across the healthcare landscape and sign up for key upcoming conferences.






